Skip to Main Content

Paper Details

Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.
Proc Natl Acad Sci U S A
37
2016
Bad, Bax, Bcl-2, Bcl-xL, Bik, HDLM-2, HDLM-2 HL, HDLM-2 tumor, HL, HL cell line, Hodgkin's Reed-Sternberg, Hodgkin's Reed-Sternberg (HRS) cells, Hodgkin's lymphoma, IL-6 and -13, JAK, JAK1/2, Mcl-1, Navitoclax, Puma, STAT, STAT3, STAT6, anti-CD30 toxin conjugate, brentuximab vedotin, c, c-Myc, caspase-9 and -3, cytochrome c, human, mice, murine, patients, poly(ADP ribose), poly(ADP ribose) polymerase, ruxolitinib, tumor
Author NameAffiliation
Xiaohu ZhangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Marc FerrerDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
  • 1 - 5

Datasets

Release 1.2